Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
PaperCitations, authors & open-access status
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 300 citations, 2022 year and green oa status.
300
Citations
2022
Year
green
OA Status